BeiGene, Ltd. (BGNE)

Market Cap	18.96B
Revenue (ttm)	3.35B
Net Income (ttm)	-854.42M
Shares Out	106.25M
EPS (ttm)	-8.19
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	59,169
Open	178.63
Previous Close	176.50
Day's Range	177.79 - 179.93
52-Week Range	126.97 - 248.16
Beta	0.60
Analysts	Buy
Price Target	253.69 (+42.16%)
Earnings Date	Nov 12, 2024

About BGNE

BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. Its commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of PARP1 and PARP2 enzymes that is being evaluated as a monotherapy ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 3, 2016
• Employees: 10,600
• Stock Exchange: NASDAQ
• Ticker Symbol: BGNE
• Website: https://www.beigene.com

Financial Performance

In 2023, BeiGene's revenue was 2.46 billion, an increase of 73.65% compared to the previous year's 1.42 billion. Losses were -881.71 million, -56.00% less than in 2022.

Financial numbers in CNY

Analyst Forecast

According to 8 analysts, the average rating for BGNE stock is "Buy." The 12-month stock price forecast is $253.69, which is an increase of 42.16% from the latest price.

Price Target

$253.69

(42.16% upside)

Analyst Consensus: Buy